Menar­i­ni Group and Sci­Clone Phar­ma­ceu­ti­cals ink deal to com­mer­cial­ize drug in Chi­na; Cel­sion to change its name

Menar­i­ni’s Asia-Pa­cif­ic sub­sidiary and Sci­Clone Phar­ma­ceu­ti­cals have en­tered in­to a li­cens­ing agree­ment to de­vel­op and even­tu­al­ly com­mer­cial­ize the drug Va­borem in Chi­na.

The deal is meant to ad­dress the pub­lic health threat of an­timi­cro­bial-re­sis­tant in­fec­tions, specif­i­cal­ly car­bapen­em-re­sis­tant Kleb­siel­la pneu­mo­nia (CRKP) in­fec­tions in Chi­na. The drug is cur­rent­ly used in the EU to treat uri­nary tract in­fec­tions, hos­pi­tal-ac­quired pneu­mo­nia and in­tra-ab­dom­i­nal in­fec­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER